ARCT News and Press, Arcturus Therapeutics Ltd. From 08/11/20

Potential for highly differentiated COVID-19 vaccine profile with a single administration, at a low dose Clinical study data expected in Q4 2020 SAN DIEGO, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”...

Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2020 Earnings Conference Call August 10, 2020 4:30 PM ET Company Participants Neda Safarzadeh - Head of Investor Relations, Public Relations & Marketing Joseph Payne - President & Chief Executive Officer Andy Sassine - Chief F...

Without naming China, Singapore researchers ( Le Bert et al. 2020 ) suggest that T cell cross-reactivity to COVID-19 viral epitopes found in all 23 persons tested 17 years after recovering from the 2003 SARS may "explain some of the differences in infection rates or pathology observed duri...

Arcturus Therapeutics (NASDAQ: ARCT ) : Q2 GAAP EPS of -$0.55 beats by $0.02 . More news on: Arcturus Therapeutics Holdings Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

COVID-19 STARR™ mRNA vaccine candidate, ARCT-021 (LUNAR-COV19) has initiated Phase 1/2 clinical study with Duke-NUS Medical School; Dosing anticipated imminently, initial data expected Q4 ARCT-810 (LUNAR-OTC), mRNA therapeutic candidate for ornithine transcarbamylase (OTC) defi...

Quick Take CureVac ( CVAC ) intends to raise $200 million from the sale of its common stock in an IPO, plus another $118 million from a concurrent private placement, according to an amended registration statement . The company is advancing a number of drug development and gene therapy pro...

Quick Take CureVac B.V. ( CVAC ) has filed to raise $100 million in an IPO of its common shares, according to an F-1 registration statement . The firm is developing a wide range of treatments, vaccines and therapies based on messenger RNA technologies. CVAC has developed extensive colla...

SAN DIEGO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportun...

Where can you find the most explosive growth? With small-cap stocks. That's true with nearly any sector. And it's certainly true when it comes to investing in companies focused on fighting COVID-19. There are many small biotechs developing experimental COVID-19 therapies and vaccine candidates....

The collective effort of pharmaceutical companies to develop a safe and effective coronavirus vaccine is often referred to as a "race", but it's not clear investors understand what the race is against. The "race" doesn't pit one company against another, as the typical first-to-market advantage d...